arGEN-X
arGEN-X offers a platform for antibody lead choice that supports the discovery of human antibody therapeutics.
Business Model:
Revenue: $0
Employees: 501-1,000
Industries / Tags:
Detailed arGEN-X Information
Geographic Data
Address:
City: Rotterdam
State: Zuid-Holland
Zip:
Country: The Netherlands
Financial Info
Stage:
post ipo equity
Raised Last:
$999M
Raised Total:$2B
Social
Metrics
325,355Website Global Rank
179,067Website Monthly Traffic
Twitter Followers
Description
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Contact Phone:
Contact Email:
arGEN-X went public on 5/17/2017 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
5/17/2017
IPO Valuation:
$442M
Ticker Symbol:
ARGX
IPO Price:
$17/share
Amount Raised:
$100M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2019 | Halozyme Therapeutics | Post-IPO Equity | 0 |
| 2/2019 | Halozyme Therapeutics | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2015 | Grant | $1.7M | 6/2016 | Post-IPO Equity | 4 | $34.1M |
Burrage Capital MPM Capital Dafna Capital Management Aquila Capital Burrage Capital MPM Capital Dafna Capital Management Aquila Capital |
9/2018 | Post-IPO Equity | $300.6M | 9/2009 | Series A | 4 | $13.6M |
Forbion Capital Partners BioGeneration Ventures Erasmus MC Biomedical Fund KBC Forbion Capital Partners |
2/2010 | Series A | 7 | $4.5M |
BioGeneration Ventures Erasmus MC Biomedical Fund Forbion Capital Partners KBC Life Sciences Partners Omnes Capital Thuja Capital |
2/2021 | Post-IPO Equity | $999.4M | 11/2019 | Post-IPO Equity | $555.7M | 12/2011 | Series B | 7 | $43.8M |
Erasmus MC Biomedical Fund PMV Omnes Capital Seventure Partners OrbiMed Forbion Capital Partners OrbiMed Seventure Partners LSP BioVentures Erasmus MC Biomedical Fund PMV Omnes Capital Seventure Partners OrbiMed Forbion Capital Partners OrbiMed Seventure Partners |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
